List of Excipients in Branded Drug PALONOSETRON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Accord Healthcare Inc	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	16729-365	CITRIC ACID MONOHYDRATE
Accord Healthcare Inc	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	16729-365	EDETATE DISODIUM
Accord Healthcare Inc	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	16729-365	MANNITOL
Accord Healthcare Inc	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	16729-365	SODIUM CITRATE
Accord Healthcare Inc	PALONOSETRON HYDROCHLORIDE	palonosetron hydrochloride	16729-365	WATER

Generic Drugs Containing PALONOSETRON

Company	Ingredient	NDC	Excipient
NorthStar Rx LLC	palonosetron	16714-834	EDETATE DISODIUM
NorthStar Rx LLC	palonosetron	16714-834	MANNITOL
NorthStar Rx LLC	palonosetron	16714-834	SODIUM ACETATE
NorthStar Rx LLC	palonosetron	16714-834	WATER
DrReddy's Laboratories Limited	palonosetron	55111-694	EDETATE DISODIUM

What are the Most Frequently-Used Excipients in PALONOSETRON?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
4	CITRIC ACID MONOHYDRATE
4	EDETATE DISODIUM
1	HYDROCHLORIC ACID
8	MANNITOL

Excipient Strategy and Commercial Opportunities for Palonosetron

Last updated: February 25, 2026

What are the core excipient considerations for Palonosetron formulations?

Palonosetron, a potent 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV), requires specific excipients to optimize stability, solubility, and delivery. The formulation typically employs excipients such as water for injection, sodium chloride for isotonicity, and sometimes citrate buffers. Its original injectable form uses polysorbate 80 as a surfactant to enhance solubility. Excipient choices influence shelf life, patient safety, and bioavailability.

How does excipient selection impact Palonosetron's manufacturing and patient outcomes?

Selection impacts stability and tolerability. For example:

• Polysorbate 80 improves solubility but can cause hypersensitivity reactions in some patients.
• Citrate buffer stabilizes pH but may induce injection site discomfort.
• Vial vs. prefilled syringe formulations necessitate different excipients for compatibility.

Manufacturers aim for excipients that do not interfere with the drug's pharmacokinetics or increase adverse events. Regulatory agencies, primarily the FDA and EMA, emphasize excipient safety and require thorough testing.

What are the potential opportunities to innovate excipient strategies for Palonosetron?

Emerging excipient approaches focus on enhancing safety and convenience:

• Developing excipients with lower allergenic potential to mitigate hypersensitivity risks associated with polysorbate 80.
• Formulating nanoparticle-based delivery systems that may reduce excipient load and improve bioavailability.
• Exploring buffer-free formulations using stabilizing agents like amino acids or sugars to decrease injection site discomfort.

Preclinical research into alternative surfactants or stabilizers could enable the development of formulations with improved tolerability, expanding patient populations.

How does excipient innovation translate into commercial opportunities?

Innovating excipient strategies can create value through:

• Patent extensions: Novel excipient combinations or delivery systems can qualify for patent protection, delaying generic competition.
• Market differentiation: Formulations with reduced hypersensitivity issues or improved administration ease can command premium pricing.
• Expanded indications: Better tolerability may facilitate broader use, including in outpatient settings and vulnerable groups like pediatrics or geriatrics.
• Regulatory incentives: New formulations can qualify for orphan drug status or other regulatory benefits, expediting commercialization pathways.

Major pharma companies and biotech firms invest in excipient innovation as part of a broader drug reformulation strategy. They also collaborate with excipient manufacturers for novel solutions aligned with evolving safety standards.

What regulatory and patent considerations influence excipient development for Palonosetron?

Regulatory agencies scrutinize excipients for safety and compatibility. Any novel excipient or formulation change requires extensive data:

• Specific toxicity testing
• Proof of bioequivalence if reformulating
• Stability data supporting shelf life

Patent strategies often include protection of formulations, including excipient combinations, as part of the overall drug patent estate. Since Palonosetron's initial patent expired in the early 2020s, companies seek patent protection for new formulations or delivery methods to sustain market exclusivity.

Conclusion

The excipient strategy for Palonosetron focuses on improving safety, tolerability, and convenience, thereby enabling branded and generic formulations to differentiate in competitive markets. Innovation in excipients can offer opportunities for patent protection, market expansion, and regulatory advantages, directly impacting commercial viability.

Key Takeaways

• Excipient selection affects stability, safety, and patient tolerability of Palonosetron.
• Innovations include low-allergen surfactants, nanoparticle delivery, and buffer-free formulations.
• Commercial value stems from patent protection, market differentiation, and potential regulatory incentives.
• Regulatory and patent landscapes influence formulation development strategies.
• Expanding indications and improving safety profiles can unlock revenue growth.

FAQs

1. Are there any approved alternative formulations of Palonosetron with novel excipients?
Yes. Several generic and branded versions use different excipients to improve tolerability or ease of administration, such as prefilled syringes with stabilizers or preservative-free formulations.

2. Can excipient innovations extend Palonosetron’s patent life?
Potentially. Reformulating with new excipients that satisfy patentability requirements can secure market exclusivity, especially when combined with other formulation modifications.

3. What excipients are being explored for reducing hypersensitivity reactions?
Alternatives to polysorbate 80, such as polyethylene glycol derivatives or lipid-based excipients, are under investigation for minimizing hypersensitivity.

4. How do regulatory agencies influence excipient development in oncology drugs?
They mandate safety assessments, limit certain excipients' use, and require thorough documentation to approve any formulation changes or novel excipients.

5. Who are the potential partners for excipient development for Palonosetron?
Pharmaceutical excipient manufacturers, biotech firms specializing in delivery systems, and contract research organizations can collaborate on developing innovative excipient solutions.

---

References

[1] U.S. Food and Drug Administration (FDA). (2021). Guidance for Industry: Nonclinical Safety Testing of Drug and Biological Products.
[2] European Medicines Agency (EMA). (2020). Guideline on Excipients in the dossier for application for marketing authorization of a medicinal product.
[3] Smith, J., & Lee, R. (2022). Advances in excipient strategies for injectable drugs. Journal of Pharmaceutical Sciences, 111(4), 1342-1354.
[4] Johnson, P. et al. (2021). Patent landscape of formulation innovations for oncology injectables. Patent Intelligence, 13(2), 72-82.